New drug could unlock kidney transplants for sensitized kids
NCT ID NCT05753930
First seen May 01, 2026 · Last updated Jun 20, 2026 · Updated 6 times
Summary
This trial tests a drug called imlifidase in highly sensitized children aged 1-17 who need a kidney transplant. The drug aims to quickly clear antibodies that would normally cause rejection, turning a positive crossmatch negative and allowing the transplant to happen. Researchers will check if the drug works and how well the new kidney functions over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Great Ormond Street Hospital for Children NHS Foundation Trust
RECRUITINGLondon, WC1N 3JH, United Kingdom
Contact
Contact
-
HUS, Helsinki University Hospital
WITHDRAWNHelsinki, 00290, Finland
-
Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
RECRUITINGBarcelona, 08035, Spain
Contact Email: •••••@•••••
Contact
-
Karolinska University Hospital
RECRUITINGHuddinge, Stockholm County, SE-141 86, Sweden
Contact Email: •••••@•••••
Contact
-
Robert Debre University Hospital
RECRUITINGParis, 75019, France
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imlifidase
What this could lead to
If it works, this could help highly sensitized children receive a kidney transplant that would otherwise be impossible due to immune rejection.
What could go wrong
This is a small, early-phase trial with only 10 participants. The drug may not work for all, and there are risks from the transplant and immune-suppressing medications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.